Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Md., Dec. 4 MedImmune today announced that,it has ... chronic asthma to,determine the safety of subcutaneous dosing of ... (IL-5R). Preclinical data,suggest that inhibiting the IL-5R pathway may ... supporting continued study of this antibody. , ...
... Azur Pharma Limited ("Azur") today,announced that it has ... ("BioSante")(Nasdaq: BPAX ) to acquire U.S. ... formulation of estradiol which is,indicated for the treatment ... Elestrin was approved by the U.S. Food and ...
... Introduces New Trade Name Onrigin(TM) for Laromustine , , ... (OTC Bulletin Board: VION) today made several announcements related to events ... the Moscone Center in San Francisco from December 6-9, 2008. ... , , The Company announced ...
Cached Biology Technology:MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 4
(Date:4/23/2014)... study by a University of Exeter researcher has shed ... wild camels thriving in Australia,s remote outback have become ... , Sarah Crowley, of the Environment and Sustainability Institute ... history of the camel in Australia, from their historic ... their current status as unwelcome "invader." , The deserts ...
(Date:4/23/2014)... (April 23, 2014). "I think one can argue that if ... as doing everything else that we canthen we can solve ... one of the world,s foremost climate researchers, in the current ... by SAGE. Refusing to take significant action on climate change ... needed to address the problem, Wigley explains in an exclusive ...
(Date:4/22/2014)... April 22, 2014 Scientists from the Florida campus ... protein complex that plays a critical but previously unknown ... study, which showed a novel role for a protein ... the journal eLife , a publisher supported by ... and the Wellcome Trust. , "This is a critical ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2Scientists identify critical new protein complex involved in learning and memory 2
... months of the First World War, a lethal virus ... swept the United States, Europe and Asia in three ... claimed up to 100 million victims, most of whom ... pneumonia. Many died within days of the first symptoms. ...
... by too many people, according to a new report published ... a Cell Press publication. Rather, the researchers found that the ... Indian Ocean depended mostly on the complexity of the reefs ... the shores., Specifically, they found, overfishing is at its worst ...
... to direct chemical modifications to specific sites on recombinant ... the pharmaceutical industry has been developed by Carolyn ... Energy,s Lawrence Berkeley National Laboratory and the University of ... for diabetes, can be made in bacterial systems like ...
Cached Biology News:Shades of 1918? New study compares avian flu with a notorious killer from the past 2Shades of 1918? New study compares avian flu with a notorious killer from the past 3Shades of 1918? New study compares avian flu with a notorious killer from the past 4Shades of 1918? New study compares avian flu with a notorious killer from the past 5Rise or fall of reef fish driven by both economy and ecology 2Tailor-made recombinant proteins in mammals 2Tailor-made recombinant proteins in mammals 3Tailor-made recombinant proteins in mammals 4
... Quansys Biosciences Q-Plex Array is a new ... human, mouse, and rat research. The Q-Plex ... ELISA-based test where 4 distinct capture antibodies ... a 96-well plate in a defined array. ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
...
Biology Products: